Brian A. Droz

1.1k total citations
10 papers, 318 citations indexed

About

Brian A. Droz is a scholar working on Molecular Biology, Physiology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Brian A. Droz has authored 10 papers receiving a total of 318 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Physiology and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in Brian A. Droz's work include Adipose Tissue and Metabolism (4 papers), Receptor Mechanisms and Signaling (3 papers) and Diet and metabolism studies (3 papers). Brian A. Droz is often cited by papers focused on Adipose Tissue and Metabolism (4 papers), Receptor Mechanisms and Signaling (3 papers) and Diet and metabolism studies (3 papers). Brian A. Droz collaborates with scholars based in United States and United Kingdom. Brian A. Droz's co-authors include Kyle W. Sloop, Tamer Coşkun, Ricardo J. Samms, Tong Sun Kobilka, Aaron D. Showalter, Masanori Fukazawa, David B. Wainscott, Dan Feng, Yoshiyuki Suzuki and Hitoshi Yoshino and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Diabetes.

In The Last Decade

Brian A. Droz

10 papers receiving 308 citations

Peers

Brian A. Droz
Thomas B. Farb United States
Jonathan W. Day United States
Weiwen Hu China
Brian M. Moran United Kingdom
Lisa Getty‐Kaushik United States
Patricio Atanes United Kingdom
Thomas B. Farb United States
Brian A. Droz
Citations per year, relative to Brian A. Droz Brian A. Droz (= 1×) peers Thomas B. Farb

Countries citing papers authored by Brian A. Droz

Since Specialization
Citations

This map shows the geographic impact of Brian A. Droz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian A. Droz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian A. Droz more than expected).

Fields of papers citing papers by Brian A. Droz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian A. Droz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian A. Droz. The network helps show where Brian A. Droz may publish in the future.

Co-authorship network of co-authors of Brian A. Droz

This figure shows the co-authorship network connecting the top 25 collaborators of Brian A. Droz. A scholar is included among the top collaborators of Brian A. Droz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian A. Droz. Brian A. Droz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Collins, Kyla, Xinxin Yu, Brian A. Droz, et al.. (2023). GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice. Diabetes. 73(2). 292–305. 8 indexed citations
2.
Samms, Ricardo J., Guofang Zhang, Olga Ilkayeva, et al.. (2022). Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Molecular Metabolism. 64. 101550–101550. 63 indexed citations
3.
Samms, Ricardo J., Richard Cosgrove, Brian A. Droz, et al.. (2022). GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior. Diabetes. 71(7). 1410–1423. 46 indexed citations
4.
Kawai, Takahiro, Bingfa Sun, Hitoshi Yoshino, et al.. (2020). Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences. 117(47). 29959–29967. 123 indexed citations
5.
Antonellis, Patrick J., Brian A. Droz, Richard Cosgrove, et al.. (2019). The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis. Molecular Metabolism. 30. 131–139. 30 indexed citations
6.
Droz, Brian A., Charles V. Jackson, M. Dodson Michael, et al.. (2017). Correlation of disease severity with body weight and high fat diet in the FATZO/Pco mouse. PLoS ONE. 12(6). e0179808–e0179808. 14 indexed citations
7.
Esbenshade, Timothy A., Arthur A. Hancock, Robert S. Bitner, et al.. (2006). Distinctions and contradistinctions between antiobesity histamine H3 receptor (H3R) antagonists compared to cognition-enhancing H3 receptor antagonists. Inflammation Research. 55(S1). S42–S44. 11 indexed citations
8.
Bush, Eugene N., Robin Shapiro, Michael E. Brune, et al.. (2006). Chronic Treatment with Either Dexfenfluramine or Sibutramine in Diet-Switched Diet-Induced Obese Mice. Endocrine. 29(2). 375–382. 9 indexed citations
9.
Hancock, Arthur A., Thomas A. Fey, Eugene N. Bush, et al.. (2005). Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflammation Research. 54(S1). S27–S29. 13 indexed citations
10.
Beaudet, Alain, O. Trémeau, A. Ménez, & Brian A. Droz. (1979). [Visualization of opiate receptors in the locus coeruleus of rats: high resolution radioautography after administration of a tritiated met-enkephalin analog].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 289(7). 591–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026